.gif "IP Gear")
- Joined
- Feb 3, 2009
- Messages
- 46
Does anyone know exactly how the c17-aa process to make certain oral agents able to bypass the liver works?
In particular, I would like to know if the c17-aa process is applied to (1) *only* the active ingredient in the agent [such as methandrostenolone for Dianabol] or (2) the *entire tablet*, meaning the active ingredient plus fillers, coloring, starches, etc.
I ask this because when taking D-bol with low milligram tablets, you must take 8-10 per day to achieve a working dose. If the c17-aa process applies to the whole tablet then this would obviously stress the liver much more than taking a single high dosage tablet. But if the process is only applied to the active ingredient in the agent, then the number of tablets should not make a difference concerning liver stress.
Any thoughts?
In particular, I would like to know if the c17-aa process is applied to (1) *only* the active ingredient in the agent [such as methandrostenolone for Dianabol] or (2) the *entire tablet*, meaning the active ingredient plus fillers, coloring, starches, etc.
I ask this because when taking D-bol with low milligram tablets, you must take 8-10 per day to achieve a working dose. If the c17-aa process applies to the whole tablet then this would obviously stress the liver much more than taking a single high dosage tablet. But if the process is only applied to the active ingredient in the agent, then the number of tablets should not make a difference concerning liver stress.
Any thoughts?
